What is the dosage of Sprycel (dasatinib)?

From the Guidelines

The recommended dosage of Sprycel (dasatinib) is 100 mg once daily.

Dosage Information

• The dosage of dasatinib can vary depending on the phase of chronic myeloid leukemia (CML) being treated, with 100 mg once daily being the recommended starting dose for patients with chronic-phase CML 1.
• For patients with accelerated- or blast-phase CML, the recommended starting dose is 140 mg once daily 1.
• Dose adjustments may be necessary in cases of hematopoietic toxicity, such as neutropenia or thrombocytopenia, with specific guidelines provided for dasatinib in the management of cytopenias 1.

Key Considerations

• Dasatinib has been shown to be effective in inducing cytogenetic and hematologic responses in patients with imatinib-resistant or imatinib-intolerant CML, with a favorable safety profile 1.
• Pleural effusion is a potential adverse effect of dasatinib, and patients with a history of cardiac disease, hypertension, or prior cardiac history may be at increased risk 1.
• The selection of dasatinib as a first-line therapy should be based on treatment goals, age, and comorbidities, and should take into consideration the adverse event profile of the available drugs 1.

From the FDA Drug Label

The recommended starting dosage of dasatinib tablets for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of dasatinib tablets for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily The recommended starting dosage for pediatrics is based on body weight as shown in Table 1. Table 1: Dosage of Dasatinib Tablets for Pediatric Patients Body Weight (kg) Daily Dose (mg) 10 to less than 20 40 mg 20 to less than 30 60 mg 30 to less than 45 70 mg at least 45 100 mg

The dosage of Sprycel (dasatinib) is:

• 100 mg once daily for adults with chronic phase CML
• 140 mg once daily for adults with accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL
• For pediatric patients, the dosage is based on body weight:
  • 40 mg once daily for patients weighing 10 to less than 20 kg
  • 60 mg once daily for patients weighing 20 to less than 30 kg
  • 70 mg once daily for patients weighing 30 to less than 45 kg
  • 100 mg once daily for patients weighing at least 45 kg 2

From the Research

Dosage of Sprycel (Dasatinib)

The recommended dosage of Sprycel (dasatinib) varies depending on the phase of chronic myeloid leukemia (CML) or the type of leukemia being treated.

• For patients with chronic CML, the recommended dose is 100 mg once daily 3, 4, 5, 6.
• For patients with accelerated phase or myeloid or lymphoid blast phase CML, or for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the recommended dose is 140 mg once daily 3, 6.
• However, a study also suggests that a lower dose of 50 mg daily may be effective and better tolerated for newly diagnosed chronic-phase CML 7.

Key Considerations

• The dosage of dasatinib may need to be adjusted based on the patient's response to treatment and the occurrence of adverse events 3, 4, 5, 6.
• Dasatinib is generally well tolerated, but common adverse events include myelosuppression, fluid retention, and gastrointestinal symptoms 3, 4, 5, 6.